Prescient Therapeutics (ASX:PTX) Other Income (Expense) : A$3.11 Mil (TTM As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Other Income (Expense)?

Prescient Therapeutics's other income expense for the Prescient Therapeutics's pretax income for the six months ended in Dec. 2023 was A$1.94 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$3.11 Mil.

Prescient Therapeutics Other Income (Expense) Historical Data

The historical data trend for Prescient Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Other Income (Expense) Chart

Prescient Therapeutics Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Income (Expense)

Get a 7-Day Free Trial

1.68

1.11

1.22

1.95

2.42

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Income (Expense)	Get a 7-Day Free Trial															0.87	1.08	1.26	1.17	1.94

Prescient Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.11 Mil.

Prescient Therapeutics (ASX:PTX) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Prescient Therapeutics (ASX:PTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines